A Study Comparing Pharmacokinetic and Safety of QL2109 and DARZALEX FASPRO® in Healthy Adults

NCT06371534 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Tumor

Interventions

DRUG: QL2109
DRUG: DARZALEX FASPRO®

Sponsor

Qilu Pharmaceutical Co., Ltd.